Detailed explanation of all possible side effects of Vibutuximab and strategies to deal with it

Vibutuximab is a targeted therapy drug that has shown great potential in the fields of Hodgkin's lymphoma, anaplastic large cell lymphoma, peripheral T-cell lymphoma, mycosis fungoides and large B-cell lymphoma. However, like other drugs, velbutuximab may cause a range of side effects during use. Understanding these side effects is critical for patients and doctors to develop appropriate treatment plans.

First, progressive multifocal leukoencephalopathy (PML) is a rare but extremely serious brain infection that has been reported in patients taking this drug. Symptoms of PML may last for weeks or months and include mood or behavior changes, confusion, thinking problems, memory loss, vision or speech difficulties, difficulty walking, and loss of strength on one side of the body. Patients should notify their oncology care team immediately if these symptoms occur.

Low white blood cell counts and an increased risk of infection are also common side effects of velbutuximab. White blood cells are critical for fighting infection, and a drop in white blood cell counts during treatment can make patients more susceptible to infection. Therefore, patients should inform their doctor promptly when they develop fever, sore throat, shortness of breath, cough and other symptoms.

Peripheral neuropathy manifests as numbness or tingling in the hands and/or feet, which may worsen. For some patients, symptoms may gradually disappear after stopping the drug, but they may not fully recover. Therefore, patients should report relevant symptoms to their doctors promptly.

A low platelet count may lead to an increased risk of bleeding. Patients should pay close attention to excessive bruising or bleeding, such as nosebleeds, bleeding gums, or bloody stools. If the platelet count is too low, the patient may need to receive a platelet transfusion.

A low red blood cell count (anemia) can make a person feel tired or weak. If symptoms such as shortness of breath, difficulty breathing, or chest pain occur, patients should promptly inform the oncology care team. If the red blood cell count is too low, the patient may need a blood transfusion.

Fatigue is very common during cancer treatment and is often not relieved by rest. Patients may need to adjust their schedule to manage fatigue, such as planning times to take breaks during the day to conserve energy for more important activities. Exercise can also help combat fatigue, such as taking a daily walk with a friend.

Nasty andVomiting or vomiting is one of the common side effects of velbutuximab. Patients can talk to their doctor so that medications can be prescribed to manage these symptoms. Also, dietary modifications may help, such as avoiding greasy, spicy, or acidic foods.

When you have diarrhea, your doctor can recommend medications to relieve symptoms. Patients can also try eating low-fiber, bland foods. Rash is one of the possible side effects. Patients can use alcohol-free moisturizers to keep their skin moisturized and avoid moisturizers with perfumes or scents. If the itching is severe or the skin cracks or bleeds, inform your doctor promptly.

In addition, velbutuximab may cause important but uncommon side effects, such as infusion-related reactions/anaphylaxis, liver toxicity, lung problems, tumor lysis syndrome, Stephen & Johnson syndrome, gastrointestinal tears/pancreatitis, and high blood sugar. These side effects may have a serious impact on patients, so patients need to pay close attention to changes in their symptoms and communicate with the medical team in a timely manner.

In summary, velbutuximab may cause a variety of side effects during treatment. Patients and medical teams should fully understand these side effects and their coping strategies so that they can adjust the plan in a timely manner during the treatment process to ensure the safety and effectiveness of the treatment. At the same time, patients also need to pay close attention to changes in their symptoms. If any discomfort or abnormal reaction occurs, they should seek medical treatment immediately and inform the doctor.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris